Website - Coming Soon PREV NEXT We are a biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies to treat ophthalmic disease. He also serves as chairman of the board of directors of two private companies, NextPoint Therapeutics and Orna Therapeutics and as a member of the board of directors of ElevateBio, also a private company. Our Commitment. The enterprise value of the merger is $1.5 billion, with the combined company expected to have an estimated $584 million in cash after closing. Xtuit Pharmaceuticals. We seek to partner with future literate entrepreneurs who understand our unique time and place in history, and who possess the ambition to author a better future for . Through a combination of internal expertise and external relationships, Cullinan manages a portfolio of pre-clinical and clinical studies with quality and precision. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T . To systemically evaluate cell-intrinsic regulators of antitumor immunity, we developed an in vitro and in vivo CRISPR screening using the murine KP lung cancer model (Fig. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working tier of immuno-oncology. We are motivated by our mission to develop potentially curative genome editing. Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Alector, Cullinan Oncology, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others. innovation. More by Interplay Learning. Today, Lyocentre historic R&D has become Nexbiome Therapeutics. Driven by an interest in how parts work together, whether in a biological system or a research team, Sarah works with other members of the Molecular Biology department to develop Strand's mRNA vector toolkit. Reporting to the Chief Scientific Officer, the Vice President Clinical Development will be responsible for . Ex Vivo Therapies. We'd love to hear from you. Ansbert K. Gadicke is an entrepreneur who founded MPM Capital Inc, MPM BioEquities Adviser LLC and Cerimon Pharmaceuticals, Inc. This approach is designed to complement natural tumor recognition, direct V9V2 T cells to the . Currently, he is President and CEO of two early-stage biotech companies, Rekindle Therapeutics and NextPoint Therapeutics. intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. The Company was founded on the successful concept of cancer immune . is a cofounder of NextPoint Therapeutics Inc. Sarah is a Scientist leading Vector Engineering efforts at Strand Therapeutics. At iTeos, we are specializing in targeted immunotherapies for people living with cancer. Iksuda is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics. Our novel Gammabody platform generates bispecific gamma delta T cell engager therapeutics that activate a unique and relatively abundant effector gamma delta T cell subset called V9V2 (Vgamma9 Vdelta2) T cells. Since July 2020, Ms. Birch has served . Age : 63. He holds the position of Managing Director at MPM Capital Inc . These charts show the average base salary (core compensation), as well as the average total cash compensation for the job of Senior Scientist in Boston, MA. Inspired to Innovate for Patients With Ophthalmic Disease. Ansbert K. Gadicke. The results show 92% of voted shares were in support of the deal. Prior to joining MPM, Detlev was the President and CEO . Most marketed immunotherapies inhibit two proteins in particular: PD-L1 on tumor cells and PD-1 on T cells. Dr. Matthew Roden is the President and CEO and serves on the board of Aktis Oncology, an MPM portfolio company. Our team of drug development veterans work closely with trusted clinical and research partners to advance candidates in both a timely and capital-efficient way. With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer. Kiddy - Reward Kids For Good Behavior - Parenting. to transform cancer therapy. CM Life Sciences II in an 8-K filing said its stockholders approved the proposed merger with SomaLogic. We'd love to talk to you. This net worth estimate does not reflect any other investments that Dr. Gadicke may own. Dr. Detlev Biniszkiewicz is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. . (888) 929-NEXT. iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients. Founded and. iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) . Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Our science. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. We are currently looking to add a Vice President Translational. Jean Birch joined the board on, and has served as NextPoint's Lead Director since, July 2, 2021, when the Company's completed its qualifying acquisition. iOmx Therapeutics focuses on the development of next-generation, first-in-class cancer immune-checkpoint inhibitors. Public asset : 3,778,634 USD. Summary NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. 6 Departments of Neurology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA. X Also called gene editing. Get new jobs for NextPoint Therapeutics by email Follow NextPoint Therapeutics Dr. Zang is professor of microbiology & immunology, of medicine, of urology, the Louis Goldstein Swan Chair in Cancer Research at Einstein, and a member of the These are targeted therapies that safely harness the superior anticancer potency of alpha-emitting . NextPoint Therapeutics is an exciting early stage Boston-area startup company working at the frontier of immune-oncology. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . . INVESTMENT PORTFOLIO (unaudited)(continued) As of June 30, 2021 NexPointStrategicOpportunitiesFund Shares Value ($) Rights-0.2% UTILITIES - 0.2% 1,624,994 Butterfly Network and Longview Acquisition announced today that they have entered into a definitive merger agreement. 3.3 star. Fully engaging the T-cell receptor to transform the treatment of solid tumors. arrow_forward. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -13.44 and . Chief Executive Officer and a member of the board of directors of Rekindle Therapeutics and NextPoint Therapeutics. The business combination is expected to close by the end of the first quarter in 2021, and the company will be SkillMill. Engineered T-cell receptor complex. September 1, 2021. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Every day, more than 500 researchers and staff come to work at Intellia. Eli5ed : Explain-ed like I am 5. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Questions about Nextpoint? NextPoint Therapeutics 650 E. Kendall Street Cambridge MA 02142 United States Tel: (617) 319 7755 Currently, there are no jobs for this employer on BioSpace. April 21, 2022 b Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines. Linked companies : Cullinan Oncology, Inc. - AlloVir, Inc. - TCR2 Therapeutics Inc. Summary. Learn about our pipeline. OncolowPipeline Every trial, result and timeline that matters Stay on top of all the and developments in your area of interest Know all the launch tit4e Our main goal is to develop effective therapies to improve patients' lives. NextPoint Learning is an online, on-demand learning platform for skilled trades. Prior to his tenure at BlueRock Therapeutics, Inc., Mr. Trigilio was a Director, Healthcare Investment Banking at RBC Capital Markets LLC . Turning Point Therapeutics, Inc. has a twelve month low of $23.77 and a twelve month high of $83.06. Reporting to the Chief Scientific Officer, the Vice President will build our Translational Medicine . are inventors on a pending patent (KIR3DL3 is an inhibitory receptor of the immune system and uses thereof); B.E.-G. is an employee and X.Z. Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 3 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent The Power Of. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. There was no mention of any redemptions, although the SPAC has consistently traded well above $11 since the deal was announced in March and . Matthew Roden, PhD Director Matthew Roden is President and Chief Executive Officer at Aktis Oncology, and a member of the Aktis Board of Directors. In vitro and in vivo screening identified Tsc1/Tsc2 as candidates of immune modulators in NSCLC. . OS Fund invests in entrepreneurs commercializing breakthrough discoveries in genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics. We use our genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability . In 1975, Lcr35 became the active ingredient of the first microbiome-derived medicinal product in the world: Antibiophilus. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Mira Therapeutics. Matt is also an Executive Partner at MPM Capital, serves as Chairman of Turmeric Acquisition Corporation, and is on the Boards of Directors of iTeos Therapeutics and NextPoint Therapeutics. Aventura, FL 33180 (786) 591-7001 Browse jobs with BioSpace Featured Employers here . Dr. Gadicke owns 248,170 shares of iTeos Therapeutics stock worth more than $4,541,511 as of May 17th. Driving progress across multiple technologies and solid tumor types. Since 2020, Nexbiome Therapeutics has been . Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. We're committed to the mission of advancing breakthrough science to deliver therapies that patients and eye care professionals need. Aktis Oncology is committed to transforming cancer care with novel platform technologies that will enable us to design and develop powerful precision radiopharmaceuticals. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Turning Point Therapeutics (TPTX) - The biopharmaceutical company's shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share . Find the latest MetaStat, Inc. (MTST) stock quote, history, news and other vital information to help you with your stock trading and investing. Turning Point Therapeutics (TPTX) - The biopharmaceutical company's shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share . NextPoint Therapeutics is an exciting early stage Boston-area startup company working at the frontier of immune-oncology. 5 NextPoint Therapeutics Inc., Cambridge, MA 02142, USA. We are currently seeking a highly motivated Project Manager to join our. Prior to joining Strand Therapeutics, Sarah was a . Matt also serves as Chairman of Turmeric Acquisition Corporation (NASDAQ: TMPM), and on the Boards of Directors of iTeos Therapeutics (NASDAQ: ITOS) and NextPoint Therapeutics, all MPM portfolio companies. Detlev Biniszkiewicz, Ph.D. - MPM Capital Dr. Detlev Biniszkiewicz is President and CEO of two early-stage MPM portfolio companies, Rekindle Therapeutics and NextPoint Therapeutics. Pipeline. world-class team. Currently, he is President and CEO of two early-stage biotech companies, Rekindle Therapeutics and NextPoint Therapeutics. Genome editing collectively refers to a set of technologies, including CRISPR/Cas9, that can be used to cut and modify DNA. Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 450 KENDALL ST. CAMBRIDGE 02142 MA USA Agent Name REGISTERED AGENT SOLUTIONS, INC Agent Address 44 SCHOOL STREET, SUITE 505, BOSTON, MA, 02108 Directors / Officers ANSBER GADICKE, director DETLEV BINISZKIEWICZ, director DETLEV BINISZKIEWICZ, president MATTHEW RODEN, director Cancer immunotherapies are monoclonal antibodies that prevent this tumor cell/T/NK cell interactionby binding to the tumor-cell protein or to the T/NK-cell receptor. Our mission is to enable improved clinical regimes through cre . The total cash compensation, which includes base, and annual incentives, can . Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies. NextPoint Financial Inc. (TSX: NPF.U) (TSX: NPF.WT.U) ("NextPoint") announced today that pursuant to NextPoint's previously announced application, the Ontario Securities Commission (the "OSC"), as . Delivering targeted alpha-emitting drugs with precision pharmacology. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Latest News. Learn More about Ansbert Gadicke's net worth. X Also called gene editing. Faber Daeufer & Itrato is a boutique law firm providing corporate and transactional counsel in the drug, life sciences, and emerging technology industries. Genome editing collectively refers to a set of technologies, including CRISPR/Cas9, that can be used to cut and modify DNA. Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share. NextPoint Learning is an online, on-demand learning platform for skilled trades. Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2021 it entered into agreements with 13 new companies. May 10, 2022 a Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update. The base salary for Senior Scientist ranges from $143,176 to $175,626 with the average base salary of $158,934. In addition, Adimab announced the expansion of 14 of its current partnerships and the achievement of 52 technical and development milestones across numerous collaborations. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public . 4.1 star. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center May 2, 2022 Pipeline. The estimated net worth of Ansbert Gadicke is at least $4.54 million as of September 13th, 2021. TCR 2 researcher at the lab bench. Director of iTeos Therapeutics. At Intellia, we are building a full-spectrum, product-driven biotechnology company focused on our mission of developing and commercializing potentially curative genome editing. Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). TCR Therapeutics. We are currently seeking a highly motivated Project Manager to join our team. HURST, Texas, May 06, 2022 (GLOBE NEWSWIRE) -- NextPoint Financial Inc. (TSX: NPF.U, NPF.WT.U and OTC Pink: NACQF) ("NextPoint") today announced that Scott Wright has been named Chief . Therapeutics pipeline. X4 Pharmaceuticals (Arsanis) Xactly (Centive) Xant (f/k/a InsideSales) Xfund2 (Experiment Fund II) Xpressdocs. Nextpoint Therapeutics, Inc. in Cambridge, MA | Company Info & Reviews Company Information Company Contacts ANSBER GADICKE Director 450 Kendall St. Cambridge, MA 02142 DETLEV BINISZKIEWICZ Director 450 Kendall St. Cambridge, MA 02142 DETLEV BINISZKIEWICZ President 450 Kendall St. Cambridge, MA 02142 STEPHEN CURTIS Director 450 Kendall St. scientific founders. NEXTPOINT THERAPEUTICS, INC. DELAWARE CORPORATION: WRITE REVIEW: Address: Corporation Trust Center 1209 Orange St Wilmington, DE 19801: Registered Agent: The Corporation Trust Company: Filing Date: September 17, 2018: File Number: 7059407: Contact Us About The Company Profile For Nextpoint Therapeutics, Inc. By systematically screening human tumor cells, the Company has identified a number of novel targets and is building a pipeline of drug candidates against them. 18851 NE 29th Ave. 2nd Floor. Nexbiome Therapeutics was built on this heritage, made of innovation and audacity, and validated R&D assets. The team aims to leverage the project's results to launch a phase 1 clinical trial in RCC patients to study the safety and efficacy of the developed antibodies and are partnered with NextPoint Therapeutics to work on pharmaceutical development for their antibody cancer therapy. Miami. FACT SHEET Q1 2021 Symbol Class A: HMEAX Class C: HMECX Class Z: HMEZX2 Inception Date (Class Z) January 20, 2015 Fund Manager Jim Dondero, CFA, Co-Founder Eric Fritz, Portfolio Manager Brad Heiss, CFA, Portfolio Manager Merger Arb Deals 53 CHICAGO, IL, OCTOBER 27, 2021 Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. 7 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working tier of immuno-oncology. xingxing.zang@einsteinmed.org. Let's Talk! Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. 1 minute read. Dr. Detlev Biniszkiewicz is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. Competing interests: Y.W., X.R., S.M., and X.Z. The company serves the Canadian medical and adult-use markets with its brand portfolio that includes: 48North, an innovative and high-quality cannabis brand focused on thoughtfully crafted . YourBioHealth (formerly Seventh Sense Biosystems) Zilker Ultimate Topco, Inc. (d/b/a ESO) (Emergency Reporting) Zingdom / Convoq. We are currently looking to add a Vice President Clinical Development to our fast moving, roll-up your sleeves team environment. 4043 N Ravenswood Ave, #317, Chicago, 60613. hello@nextpoint.com. Learn about our science. 1A).KP cells were engineered to express Cas9, and two clonal KP-Cas9 cell lines (clones 7 and 9) were selected to provide . Prior to that, Dr. Biniszkiewicz served as President and Chief Executive . Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held several senior The other authors declare that they have no competing interests. NEW YORK& SAN DIEGO---- Bristol Myers Squibb and . We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment.